Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study - PubMed
4 hours ago
- #Benign Prostatic Hyperplasia
- #Type 2 Diabetes
- #5-Alpha Reductase Inhibitors
- This study assessed the risk of type 2 diabetes mellitus (T2DM) in new users of 5-alpha reductase inhibitors (5-ARIs), specifically finasteride and dutasteride, compared to tamsulosin in patients with benign prostatic hyperplasia (BPH) in South Korea.
- Using a nationwide historical cohort from 2010 to 2020, the study included 34,874 tamsulosin users, 16,953 finasteride users, and 19,480 dutasteride users without prior T2DM or recent prescriptions of these drugs.
- After adjusting for risk factors via stabilized inverse probability of treatment weighting, finasteride showed a slightly increased risk of T2DM with an adjusted hazard ratio of 1.06, while dutasteride showed no significant risk with a ratio of 0.97, compared to tamsulosin.
- The findings remained consistent in lag time analyses and were attenuated among patients with good compliance, suggesting minimal effects of both 5-ARIs on T2DM risk relative to tamsulosin.
- The study concluded that finasteride and dutasteride have minimal impact on the risk of developing T2DM compared to tamsulosin in BPH patients, with no significant overall increase.